Home/ Stocks/ DNLI

Denali Therapeutics Inc. Common Stock

DNLI XNAS

$24.83 +0.10 (+0.40%) ▲ 15-min delayed

Open

$25.41

High

$25.74

Low

$24.23

Volume

1.75M

Market Cap

$3.92B

About Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 507 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-128,447,000	$-0.69
FY 2025	$0	$-512,540,000	$-2.97
Q3 2025	$0	$-126,902,000	$-0.74
Q2 2025	$0	$-124,119,000	$-0.72

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for DNLI yet. Check out our latest market news or earnings calendar.

Get DNLI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Denali Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.